CClinicalTrials.gg
Not yet recruitingNCT07767929Updated Sep 2, 2026

Evaluating Narrative Vaping Prevention Video Ads for Adolescents and Young Adults

An interventional study of Acted-Out Narrative Ads and Non-Acted-Out Narrative Testimonial Ads in Vaping, sponsored by UNC Lineberger Comprehensive Cancer Center. Not yet recruiting at 2 sites in United States. Open to participants aged 13 Years to 20 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by UNC Lineberger Comprehensive Cancer Center · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
1,910
Allocation
Randomized
Ages
13 Years to 20 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the persuasive effectiveness of narrative advertisements: with acted-out plots (where characters enact a vaping-related experience) versus narrative advertisements without acted-out plots and control. Using a 3-arm between-subjects randomized design, approximately 1,910 adolescents and young adults (aged 13-20) in the U.S. who vape or are susceptible to vaping will be recruited online. Participants will be randomly assigned to view video ads from one of three conditions (narrative with acted-out plots, narrative without acted-out plots, or control videos) and complete a post-exposure survey evaluating message engagement, emotional response, perceived effectiveness, and psychological reactance.

Read the detailed description

Study Rationale: Health communication campaigns are an evidence-based approach to preventing and reducing tobacco product use. Narrative messaging is widely used in public health campaigns, but research is lacking to identify which specific objective message features drive narrative persuasion. This study examines whether acted-out plots improve message engagement and reduce psychological reactance among youth. Setting \& Recruitment: Adolescent and young adult participants will be recruited by Qualtrics Services. Participants who are 18 to 20 years old and are eligible for the study will view a consent form as part of the survey and check a box to indicate that they agree to participate in the study. For minor participants, Qualtrics will recruit parents of 13-17-year-olds, so they will receive the survey invitation with the parental permission/consent form. From there, parents will be asked to pass the survey to their child. Once the participant has completed the consent/assent process, they will be able to begin the survey. Procedures: Eligible participants will complete a baseline screener assessing demographics and vaping product use. They will then be randomized in one of three conditions and view 3 video advertisements in a random order from their assigned group. Immediate post-ad measures will assess affective and evaluative responses, followed by a post-exposure questionnaire measuring vaping risk beliefs and behavioral susceptibility. After the survey, participants will view a debrief page linking them to The Real Cost website with information about tobacco use harms. The survey will take 15-20 minutes.

02

Conditions studied

  • Vaping

Browse trials for

Keywords

  • Vaping prevention
  • Health communication
  • Tobacco Use
03

Who can participate

Ages eligible
13 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age 13-20 years old.
  • Current vaper or at risk of vaping. Participants will be considered as a current vaper if they report using e-cigarettes in the past 30 days. Participants will be considered as "at-risk of vaping" if they answer anything other than "definitely not' to 3 screening items assessing their susceptibility to vaping (e.g., "If one of your best friends were to offer you a vape, would you use it?" Response options: definitely not, probably not, probably yes, definitely yes).
  • Live in the United States

Exclusion criteria

Exclusion Criteria:

  • Younger than 13 years or older than 21 years.
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,910 participants (estimated)

Study arms

  • Experimental
    Condition 1

    Acted-Out Narrative Video Ads

    Behavioral: Acted-Out Narrative Ads

  • Experimental
    Condition 2

    Non-Acted-Out Narrative Video Ads

    Behavioral: Non-Acted-Out Narrative Testimonial Ads

  • Active comparator
    Condition 3

    Control Videos

    Behavioral: Neutral Control Videos

Interventions

  • BehavioralActed-Out Narrative Ads

    Participants view 3 randomly ordered vaping prevention video ads featuring characters enacting a vaping-related experience or consequence (e.g., experiencing addiction/withdrawal symptoms).

  • BehavioralNon-Acted-Out Narrative Testimonial Ads

    Participants view 3 randomly ordered narrative testimonial video ads featuring testimonial narration with static visual presentations, without character enactment.

  • BehavioralNeutral Control Videos

    Participants view 3 neutral/informational text-and-voice-only control ads about vaping without any testimonial element.

05

What researchers measure

Primary outcomes

  1. Message engagement

    Assessed using a standard 3-item self-report scale (e.g., " I could picture myself in the scene of the events described in the ad", "I was mentally involved while watching the ad"). Responses are scored on a 1-5 Likert scale, with higher averaged scores indicating deeper engagement.

    Time frame: Baseline (after each video exposure)

Secondary outcomes

  1. Perceived Message Effectiveness

    The 3-item perceived message effectiveness scale assesses the extent to which participants perceived the vaping prevention video ads as effective. Response options are on a 5-point scale from 1="Not at all" to 5="A great deal". The overall scale score is determined by averaging scores from the 3 items, with higher scores representing higher perceived message effectiveness.

    Time frame: Baseline (after each video exposure)

  2. Negative Affect

    Negative Affect is measured via a 3-item scale assessing negative affects (e.g., "How much do these ads make you feel anxious/ Disgusted/Scared ") on a 1-5 scale, with higher scores representing higher negative affect.

    Time frame: Baseline (after each video exposure)

  3. Psychological Reactance

    Evaluated using a single-item measure of message resistance ( " How much does this ad annoy you? ") scored on a 1-5 scale, with higher scores representing higher reactance.

    Time frame: Baseline (after each video exposure)

  4. Vaping Susceptibility

    Evaluated using a 3-item index evaluating future intentions (e.g., "Do you think you will use an e-cigarette or vape in the next year?") scored on a 1-4 response scale, with higher scores representing vaping susceptibility.

    Time frame: Baseline (after each video exposure)

  5. Vaping beliefs

    Evaluated using an 8-item index evaluating future intentions (e.g., " If you vape, how likely or unlikely is it that you will… Become addicted to vaping/ Breathe in dangerous chemicals?") scored on a 1-5 response scale, with higher scores representing higher vaping beliefs.

    Time frame: Baseline (after each video exposure)

06

Study locations

2 sites
  • Fairfield University
    Fairfield, Connecticut 06824, United States
    • Ran Tao, PhD · Contact · rantao599@gmail.com · 203-254-4000
    • Ran Tao, PhD · Principal investigator
  • University of North Carolina, Chapel Hill
    Chapel Hill, North Carolina 27599, United States
07

References and documents

08

Registry details

Key details

Study ID
NCT07767929
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Collaborators
Food and Drug Administration (FDA), National Institute on Drug Abuse (NIDA)
Responsible party
Sponsor
First posted
Aug 17, 2026
Start date
Sep 2026 (estimated)
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Sep 2, 2026

Study contacts

Victoria Triana
Contact
Victoria_Triana@med.unc.edu
919-984-0000
Caroline Ritchie
Contact
Caroline_Ritchie@med.unc.edu
Seth M Noar, PhD
principal investigator · UNC Lineberger Comprehensive Cancer Center
Sarah Kowitt, PhD
principal investigator · UNC Lineberger Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion